254 related articles for article (PubMed ID: 29206651)
1. Novel therapeutic strategies and targets in advanced uveal melanoma.
Chua V; Aplin AE
Curr Opin Oncol; 2018 Mar; 30(2):134-141. PubMed ID: 29206651
[TBL] [Abstract][Full Text] [Related]
2. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
3. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic signaling in uveal melanoma.
Park JJ; Diefenbach RJ; Joshua AM; Kefford RF; Carlino MS; Rizos H
Pigment Cell Melanoma Res; 2018 Nov; 31(6):661-672. PubMed ID: 29738114
[TBL] [Abstract][Full Text] [Related]
5. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
9. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
10. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in prognostic and predictive testing in uveal melanoma.
Field MG; Harbour JW
Curr Opin Ophthalmol; 2014 May; 25(3):234-9. PubMed ID: 24713608
[TBL] [Abstract][Full Text] [Related]
12. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Mergener S; Siveke JT; Peña-Llopis S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
14. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
17. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
19. Molecular and immunohistochemical analyses of uveal melanoma patient cohort.
Sarubi HC; Pereira NB; Gomes CC; Gomez RS; Carmo ACM; Melo FM; Bastos-Rodrigues L; Pedrosa MS; Friedman E; De Marco L
Melanoma Res; 2019 Jun; 29(3):248-253. PubMed ID: 30480620
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
